Indian genericsmaker Dr Reddy's Laboratories ($RDY) had a slight uptick in earnings in the last quarter, helped along by generics sales in the U.S. It reported a profit of 3.43 billion rupees ($64.25 million) compared to a return of 3.34 billion rupees a year earlier. Its North American sales were up 36% to 8.7 billion rupees. It incurred a 1.04 billion rupee charge related to Betapharm, the company it acquired in 2006 but has had trouble integrating, Reuters reports. Dr. Reddy's is the second largest Indian genericsmaker and toils in the shadow of the much larger Ranbaxy Laboratories, which had a huge quarter tied to generic sales of Lipitor in the U.S. Story | More